GlassScriptPhysician profile
Iqbal Singh
NPI 1588654149
$1,050.00
in general payments reported to CMS, 2019-2025
21 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.36 · 2020: $51.52 · 2021: $33.96 · 2022: $152 · 2023: $198 · 2024: $263 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $198.78 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $155.06 | 2019-2024 | |
| Itamar Medical INC | $130.39 | 2022-2025 | Watchpatone |
| Abiomed | $75.49 | 2019-2022 | |
| Medtronic, INC. | $72.36 | 2025 | Symplicity G3 |
| Cvrx, INC. | $71.41 | 2023-2024 | Barostim Neo System |
| Boston Scientific Corporation | $44.96 | 2024-2025 | Accolade Sr |
| Philips North America LLC | $44.46 | 2025 | Ecc Solutions, Mcot |
| Actelion Pharmaceuticals US, INC. | $35.98 | 2019-2024 | Opsumit |
| Sanofi-Aventis U.S. LLC | $31.62 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $30.48 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.45 | 2025 | |
| Kestra Medical Technology Services, INC. | $23.36 | 2024 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.16 | 2020-2024 | Lifevest |
| Novo Nordisk INC | $16.66 | 2024 | Ozempic, Rybelsus |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $14.11 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.94 | 2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $13.35 | 2023 | Inpefa |
| Amgen INC. | $12.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.82 | 2020 | |
| Bardy Diagnostics, INC. | $9.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iqbal Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.